CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

A device designed to remove embolic material-fragments of tissue that can be released into the bloodstream during ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Mercy Health — Lourdes Hospital has officially restarted its structural heart program after Dr. Shankho Ganguli performed the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Indian-made ...